Delivery Order SPE2DB20D1109-SPE2DB22FN69L
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $4,103.68 for the supply of 4,558,237,997 units of XEOMIN 200 unit vials. The award was made by the Defense Logistics Agency (DLA), a component of the Department of Defense, and does not have any set-aside designation. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the...
- This federal contract award, valued at $86,177.28, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a Firm Fixed Price Delivery Order for the supply of 4,559,517,536 units of the pharmaceutical product XEOMIN 200 UNIT VIALS. The contract has an Ultimate Completion Date of September 12, 2022 and was awarded on August 19, 2022. This award is not associated with a set-aside designation, indicating open competition....
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,609,982 units of the pharmaceutical product XEOMIN 100 Unit Vials. The contract has a potential value of $7,715.88 and a completion date of March 1, 2024. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is not associated with any set-aside designation. Amerisourcebergen Drug Corp also...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,352.44 firm fixed-price delivery order is for the supply of 4,568,455,585 units of the pharmaceutical product XEOMIN 100 UNIT VIALS. The contract has an ultimate completion date of June 26, 2025 and is not set aside for any specific business designation. Amerisourcebergen Drug Corp holds a significant...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $25,648.00 firm fixed price delivery order is for the supply of XEOMIN 200 UNIT VIALS, a specialty medication. The award has an ultimate completion date of April 21, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company, Cencora, Inc., which maintains several Indefinite Delivery Contracts (IDCs)...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of XEOMIN 200 unit vials. The firm-fixed-price delivery order, valued at $4,193.92, has an ultimate completion date of August 11, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
- This federal contract award, valued at $13,559.00, was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a delivery order for the provision of 4,566,773,316 units of the pharmaceutical product XEOMIN 200 UNIT VIALS. The contract has a firm fixed-price pricing type and an ultimate completion date of January 13, 2025. This award is part of a larger Indefinite Delivery Contract (IDC)...
- This federal contract award was granted by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The $12,057.69 firm fixed-price delivery order is for the supply of 4,565 units of the pharmaceutical product XEOMIN 200 UNIT VIALS. The contract has a completion date of July 17, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $1,508.70 delivery order is for the supply of XEOMIN 100 unit vials, a pharmaceutical product. The award is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC...
- This federal contract award, valued at $92,332.80, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Cencora, Inc. holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for Cencora, Inc. to deliver a comprehensive range of pharmaceutical products and medical supplies, including...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB22FN69LDelivery Order
This federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $9,233.28 for 4,556,406,328 units of the pharmaceutical product XEOMIN 200 UNIT VIALS. The contract has a completion date of March 21, 2022 and was awarded on February 28, 2022. It is a firm fixed-price contract type with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp, a major pharmaceutical distributor, maintains a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare programs globally. The company also holds a separate IDC with the Department of Justice Federal Bureau of Investigation valued at up to $750,000 through May 2024 for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.2k | 2/28/22 |